Research graph
References from Identification of a shared blood–brain transcriptomic signature in Parkinson’s disease using bioinformatic and network pharmacology approaches. Local targets link to admitted publications; unresolved targets remain external evidence.
Neurodegenerative disease: brain windfall
10.1038/nj7526-299a · 2014 · External reference
10.1016/s1474-4422(17)30299-5
10.1016/s1474-4422(17)30299-5 · External reference
Intrinsically disordered proteins and their (disordered) proteomes in neurodegenerative disorders
10.3389/fnagi.2015.00018 · 2015 · External reference
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
1998 · External reference
α-synuclein: a promising biomarker for Parkinson’s disease and related disorders
10.14802/jmd.24075 · 2024 · External reference
Disruption of protein quality control in Parkinson's disease
10.1101/cshperspect.a009423 · 2012 · External reference
UCHL1 from serum and CSF is a candidate biomarker for amyotrophic lateral sclerosis
10.1002/acn3.51141 · 2020 · External reference
Impact of Parkinson's disease risk loci on age at onset
10.1002/mds.26237 · 2015 · External reference
Reference SVA insertion polymorphisms are associated with Parkinson's disease progression and differential gene expression
10.1038/s41531-021-00189-4 · 2021 · External reference
Deciphering the role of a SINE-VNTR-Alu retrotransposon polymorphism as a biomarker of Parkinson's disease progression
10.1038/s41598-024-61753-5 · 2024 · External reference
Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson’s disease
10.1038/s41467-023-39652-6 · 2023 · External reference
Longitudinal intronic RNA-Seq analysis of Parkinson's disease patients reveals disease-specific nascent transcription
10.1177/15353702221081027 · 2022 · External reference
The exon-based transcriptomic analysis of Parkinson’s disease
10.3390/biom15030440 · 2025 · External reference
Transcriptomic profiles in Parkinson's disease
10.1177/1535370220967325 · 2021 · External reference
A whole-transcriptome analysis of differentially expressed genes, transcripts, and transcript usage in blood samples from Parkinson's disease patients
10.3389/ebm.2026.11099 · 2026 · External reference
Looking beyond the brain to improve the pathogenic understanding of Parkinson's disease: implications of whole transcriptome profiling of patients' skin
10.1186/s12883-016-0784-z · 2017 · External reference
NCBI GEO: archive for functional genomics data sets–update
2013 · External reference
A screen for genes induced in the amygdaloid area during cat odor exposure
10.1046/j.1601-183x.2003.00047.x · 2004 · External reference
Linear models and empirical bayes methods for assessing differential expression in microarray experiments
10.2202/1544-6115.1027 · 2004 · External reference
10.1007/0-387-29362-0_23
10.1007/0-387-29362-0_23 · External reference
DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021update)
10.1093/nar/gkac194 · 2022 · External reference
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
10.1038/nprot.2008.211 · 2009 · External reference
Identification of common genes for neuropathic pain and Parkinson’s disease based on bioinformatics analysis and their potential value in the diagnosis of neuropathic pain
10.2147/jpr.s532016 · 2025 · External reference
Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation
10.1016/j.neurobiolaging.2009.10.016 · 2011 · External reference
The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability
10.1007/s10048-006-0077-6 · 2007 · External reference
Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease
10.1007/s10048-005-0020-2 · 2006 · External reference
Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms
10.1002/ajmg.b.30195 · 2005 · External reference
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease
10.1126/scitranslmed.3001059 · 2010 · External reference
Methyl-arginine profile of brain from aged PINK1-KO+A53T-SNCA mice suggests altered mitochondrial biogenesis
2016 · External reference
Interplay between protein glycosylation pathways in Alzheimer's disease
10.1126/sciadv.1601576 · 2017 · External reference
Sialylation in the nervous system: functions and mechanisms
10.1016/j.jbc.2026.111288 · 2026 · External reference
The potential of ANK1 to predict Parkinson's disease
10.3390/genes14010226 · 2023 · External reference
ANK1 is up-regulated in laser captured microglia in Alzheimer's brain; the importance of addressing cellular heterogeneity
10.1371/journal.pone.0177814 · 2017 · External reference
A cross-brain regions study of ANK1 DNA methylation in different neurodegenerative diseases
10.1016/j.neurobiolaging.2018.09.024 · 2019 · External reference
A convergent metabolic-kinase signaling axis links Parkinson's disease and multiple system atrophy
2026 · External reference
RELA as a diagnostic biomarker for Parkinson’s disease by integrating ferroptosis, lipid metabolism, and neuroinflammation
10.1007/s10753-026-02478-7 · 2026 · External reference
High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life
10.1096/fj.09-140368 · 2010 · External reference
The GTPase Rab27b regulates the release, autophagic clearance, and toxicity of α-synuclein
10.1074/jbc.ra120.013337 · 2020 · External reference
A review on the role of SNCA gene in neurodegenerative diseases
2024 · External reference
SNCA triplication disrupts proteostasis and extracellular architecture prior to neurodegeneration in human midbrain organoids
10.1038/s41531-026-01292-0 · 2026 · External reference
Molecular evolutionary and structural analysis of human UCHL1 gene demonstrates the relevant role of intragenic epistasis in Parkinson's disease and other neurological disorders
10.1186/s12862-020-01684-7 · 2020 · External reference
Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy
10.1016/j.gim.2022.07.006 · 2022 · External reference
UCH-L1 in Alzheimer's disease: a crucial player in dementia-associated mechanisms
10.3390/ijms26189012 · 2025 · External reference
Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII
10.1111/j.1460-9568.2007.05569.x · 2007 · External reference
Meta-analysis of differentially expressed genes in the substantia Nigra in Parkinson's disease supports phenotype-specific transcriptome changes
10.3389/fnins.2020.596105 · 2020 · External reference
Regulon reconstruction uncovers novel deregulated factors in Alzheimer’s disease
10.1007/s12035-026-05745-8 · 2026 · External reference
Proteomic characterization of the olfactory molecular imbalance in dementia with lewy bodies
10.3390/ijms21176371 · 2020 · External reference
Molecular disease stages of oligodendrocytic and neuronal tau burden in progressive supranuclear palsy
2026 · External reference
Serum lipidomics reveals class-specific lipid remodelling and altered acyl chain composition in Parkinson's disease
10.1016/j.parkreldis.2026.108425 · 2026 · External reference
